Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS

Mitsubishi Tanabe Pharma said on January 13 that an oral suspension version of its ALS therapy Radicava (edaravone) has been accepted by the US FDA for review, with a target date set for May 12 under the priority review pathway...read more